A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Clinical trial NCT07011745 · RECRUITING
Trial details
- NCT number
- NCT07011745
- Sponsor
- Bristol-Myers Squibb
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-16
- Primary completion
- 2028-11-03
- Enrollment
- 426
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.